Recent Updates on Vascular Complications in Patients with Type 2 Diabetes Mellitus

It is well known that patients with type 2 diabetes mellitus (T2DM) are at an increased risk of morbidity and mortality from atherosclerotic cardiovascular (CV) complications. Previously, the concept that diabetes mellitus (DM) is a “coronary artery disease (CAD) risk equivalent” was widely accepted...

Full description

Bibliographic Details
Main Authors: Chan-Hee Jung, Ji-Oh Mok
Format: Article
Language:English
Published: Academya Publishing Co. 2020-06-01
Series:Endocrinology and Metabolism
Subjects:
Online Access:http://www.e-enm.org/upload/pdf/EnM-2020-35-2-260.pdf
id doaj-6e54714f55e64022a8c6d731463ac168
record_format Article
spelling doaj-6e54714f55e64022a8c6d731463ac1682020-11-25T02:49:39ZengAcademya Publishing Co.Endocrinology and Metabolism2093-596X2093-59782020-06-0135226027110.3803/EnM.2020.35.2.2602041Recent Updates on Vascular Complications in Patients with Type 2 Diabetes MellitusChan-Hee JungJi-Oh MokIt is well known that patients with type 2 diabetes mellitus (T2DM) are at an increased risk of morbidity and mortality from atherosclerotic cardiovascular (CV) complications. Previously, the concept that diabetes mellitus (DM) is a “coronary artery disease (CAD) risk equivalent” was widely accepted, implying that all DM patients should receive intensive management. However, considerable evidence exist for wide heterogeneity in the risk of CV events among T2DM patients and the concept of a “CAD risk equivalent” has changed. Recent guidelines recommend further CV risk stratification in T2DM patients, with treatment tailored to the risk level. Although imaging modalities for atherosclerotic cardiovascular disease (ASCVD) have been used to improve risk prediction, there is currently no evidence that imaging-oriented therapy improves clinical outcomes. Therefore, controversy remains whether we should screen for CVD in asymptomatic T2DM. The coexistence of T2DM and heart failure (HF) is common. Based on recent CV outcome trials, sodium glucose cotransporter-2 inhibitors and glucagon like peptide-1 receptor agonists are recommended who have established ASCVD, indicators of high risk, or HF because of their demonstrated benefits for CVD. These circumstances have led to an increasing emphasis on ASCVD and HF in T2DM patients. In this review, we examine the literature published within the last 5 years on the risk assessment of CVD in asymptomatic T2DM patients. In particular, we review recent guidelines regarding screening for CVD and research focusing on the role of coronary artery calcium, coronary computed tomography angiography, and carotid intima-media thickness in asymptomatic T2DM patients.http://www.e-enm.org/upload/pdf/EnM-2020-35-2-260.pdfatherosclerosiscalciumcoronary vesselscarotid intima-media thicknessrisk assessmentdiabetes mellitustype 2
collection DOAJ
language English
format Article
sources DOAJ
author Chan-Hee Jung
Ji-Oh Mok
spellingShingle Chan-Hee Jung
Ji-Oh Mok
Recent Updates on Vascular Complications in Patients with Type 2 Diabetes Mellitus
Endocrinology and Metabolism
atherosclerosis
calcium
coronary vessels
carotid intima-media thickness
risk assessment
diabetes mellitus
type 2
author_facet Chan-Hee Jung
Ji-Oh Mok
author_sort Chan-Hee Jung
title Recent Updates on Vascular Complications in Patients with Type 2 Diabetes Mellitus
title_short Recent Updates on Vascular Complications in Patients with Type 2 Diabetes Mellitus
title_full Recent Updates on Vascular Complications in Patients with Type 2 Diabetes Mellitus
title_fullStr Recent Updates on Vascular Complications in Patients with Type 2 Diabetes Mellitus
title_full_unstemmed Recent Updates on Vascular Complications in Patients with Type 2 Diabetes Mellitus
title_sort recent updates on vascular complications in patients with type 2 diabetes mellitus
publisher Academya Publishing Co.
series Endocrinology and Metabolism
issn 2093-596X
2093-5978
publishDate 2020-06-01
description It is well known that patients with type 2 diabetes mellitus (T2DM) are at an increased risk of morbidity and mortality from atherosclerotic cardiovascular (CV) complications. Previously, the concept that diabetes mellitus (DM) is a “coronary artery disease (CAD) risk equivalent” was widely accepted, implying that all DM patients should receive intensive management. However, considerable evidence exist for wide heterogeneity in the risk of CV events among T2DM patients and the concept of a “CAD risk equivalent” has changed. Recent guidelines recommend further CV risk stratification in T2DM patients, with treatment tailored to the risk level. Although imaging modalities for atherosclerotic cardiovascular disease (ASCVD) have been used to improve risk prediction, there is currently no evidence that imaging-oriented therapy improves clinical outcomes. Therefore, controversy remains whether we should screen for CVD in asymptomatic T2DM. The coexistence of T2DM and heart failure (HF) is common. Based on recent CV outcome trials, sodium glucose cotransporter-2 inhibitors and glucagon like peptide-1 receptor agonists are recommended who have established ASCVD, indicators of high risk, or HF because of their demonstrated benefits for CVD. These circumstances have led to an increasing emphasis on ASCVD and HF in T2DM patients. In this review, we examine the literature published within the last 5 years on the risk assessment of CVD in asymptomatic T2DM patients. In particular, we review recent guidelines regarding screening for CVD and research focusing on the role of coronary artery calcium, coronary computed tomography angiography, and carotid intima-media thickness in asymptomatic T2DM patients.
topic atherosclerosis
calcium
coronary vessels
carotid intima-media thickness
risk assessment
diabetes mellitus
type 2
url http://www.e-enm.org/upload/pdf/EnM-2020-35-2-260.pdf
work_keys_str_mv AT chanheejung recentupdatesonvascularcomplicationsinpatientswithtype2diabetesmellitus
AT jiohmok recentupdatesonvascularcomplicationsinpatientswithtype2diabetesmellitus
_version_ 1724742135590158336